11.85

16.86% 1.71

After Hours: 11.56 -0.29 -2.45%

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $11.85, with a volume of 2.21M. It is up +16.86% in the last 24 hours and down -5.12% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Previous Close:

$10.14

Open:

$12.6

24h Volume:

2.21M

Relative Volume:

2.81

Market Cap:

$911.93M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-3.75

EPS:

-3.16

Net Cash Flow:

$-176.27M

1W Performance:

+12.96%

1M Performance:

-5.12%

6M Performance:

+19.82%

1Y Performance:

+57.58%

1-Day Range:

$11.48

$13.13

1-Week Range:

$10.05

$13.13

52-Week Range:

$4.92

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1176)

Industry

Biotechnology (685)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

331

Twitter

@Replimune

Next Earnings Date

2024-11-05

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	11.85	911.93M	0	-209.96M	-176.27M	-3.16
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

Jan 21, 2025

Barclays maintains Replimune stock with $17 target By Investing.com - Investing.com UK

Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment - MSN

Jan 21, 2025

Replimune Stock Soars 16% on FDA Priority Review for Advanced Me - GuruFocus.com

Jan 21, 2025

Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy - Yahoo Finance

Jan 21, 2025

Replimune stock price target raised to $27 by BMO Capital - Investing.com

Jan 21, 2025

Replimune stock soars on FDA priority review for melanoma treatment By Investing.com - Investing.com Australia

Jan 21, 2025

Replimune Group (NASDAQ:REPL) Shares Gap UpTime to Buy? - MarketBeat

Jan 21, 2025

Charles Schwab Posts Upbeat Earnings, Joins Redwire, Evolus, Replimune Group And Other Big Stocks Moving Higher On Tuesday - Benzinga

Jan 21, 2025

FDA accepts Replimune's advanced melanoma therapy BLA - Investing.com

Jan 21, 2025

Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma - The Manila Times

Jan 21, 2025

FDA Grants Priority Review to Replimune's Melanoma Treatment RP1, Breakthrough Therapy Status Secured - StockTitan

Jan 21, 2025

JPMorgan Chase & Co. Raises Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jan 21, 2025

Jan 17, 2025

Trend Tracker for (REPL) - Stock Traders Daily

Jan 17, 2025

Jan 16, 2025

Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology - MSN

Jan 16, 2025

Jan 14, 2025

Replimune Group (NASDAQ:REPL) Trading Down 6.6%Here's Why - MarketBeat

Jan 14, 2025

Jan 12, 2025

Barclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World

Jan 12, 2025

Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL) - MarketBeat

Jan 12, 2025

Jan 11, 2025

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 11, 2025

Jan 10, 2025

Replimune Awards Equity Incentives to 30 New Hires, Including 253,820 Shares in Options and RSUs - StockTitan

Jan 10, 2025